China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of its generic drug and “non-core” conventional medicine businesses. The move follows a strategic review aimed at refocusing resources on higher-growth sectors.
Strategic Rationale
The board intends to offload products not aligned with performance expectations or long-term goals. Proceeds will support investments in medical aesthetics and innovative biologics, areas with stronger growth and profit potential.
Background
In May, Sihuan reportedly held preliminary takeover talks with China Resources, with a $3 billion buyout speculated. Today’s announcement suggests those discussions did not materialize.-Fineline Info & Tech
